- Home
- LVO vs INKT Comparison
LVO vs INKT Comparison
Compare LVO & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVO | INKT |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2M | 57.6M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LVO | INKT |
|---|---|---|
| Price | $4.81 | $9.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $13.00 | ★ $35.00 |
| AVG Volume (30 Days) | 65.9K | ★ 155.7K |
| Earning Date | 02-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.57 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $114,405,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $6.66 |
| 52 Week High | $6.04 | $76.00 |
Technical Indicators
Market Signals| Indicator | LVO | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 46.51 |
| Support Level | $3.95 | $6.80 |
| Resistance Level | $5.69 | $12.64 |
| Average True Range (ATR) | 0.48 | 0.86 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 17.07 | 18.70 |
Price Performance
Historical ComparisonAbout LVO LiveOne Inc.
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.